Memòria 2010 - IISPV

Àmbit estratègic 5. Salut i medi ambient (toxicologia, microbiologia, malalties infeccioses i VIH/sida)years. Arch Intern Med. 2010; 170:410-9.FI: 9,110. 1r quartil.VIDAL F, GUTIÉRREZ F, GUTIÉRREZ M, OLONA M,SÁNCHEZ V, MATEO G, PERAIRE J, VILADÉSC, VELOSO S, LÓPEZ-DUPLA M, DOMINGO P.Pharmacogenetics of adverse effects dueto antiretroviral drugs. AIDS Rev. 2010;12:15-30. FI: 3,642. 1r quartil.ECHEVERRÍA P, NEGREDO E, CAROSI G, GÁLVEZ J,GÓMEZ JL, OCAMPO A, PORTILLA J, PRIETO A,LÓPEZ JC, RUBIO R, MARIÑO A, PEDROL E, VI-LADÉS C, DEL ARCO A, MORENO A, BRAVO I,LÓPEZ-BLAZQUEZ R, PÉREZ-ALVAREZ N, CLOTETB. Similar antiviral effi cacy and tolerabilitybetween efavirenz and lopinavir/ritonavir,administered with abacavir/lamivudine(Kivexa), in antiretroviral-naïve patients: a48-week, multicentre, randomized study(Lake Study). Antiviral Res. 2010; 85:403-8. FI: 3,613. 1r quartil.MARTÍNEZ E, LARROUSSE M, PODZAMCZER D, PÉREZI, GUTIÉRREZ F, LONCÁ M, BARRAGÁN P, DEU-LOFEU R, CASAMITJANA R, MALLOLAS J, PICH J,GATELL JM; BICOMBO STUDY TEAM (VIDAL F,PERAIRE J). Abacavir-based therapy doesnot affect biological mechanisms associatedwith cardiovascular dysfunction.AIDS. 2010; 24:F1-9. FI: 4,909. 1r quartil.HIV-CAUSAL COLLABORATION, RAY M, LOGAN R,STERNE JA, HERNÁDEZ-DÍAZ S, ROBINS JM,SABIN C, BANSI L, VAN SIGHEM A, DE WOLF F,COSTAGLIOLA D, LANOY E, BUCHER HC, VONWYL V, ESTEVE A, CASABONA J, DEL AMO J,MORENO S, JUSTICE A, GOULET J, LODI S, PHI-LLIPS A, SENG R, MEYER L, PÉREZ-HOYOS S,GARCÍA DE OLALLA P, HERNÁN MA (VIDAL F).The effect of combined antiretroviral therapyon the overall mortality of HIV-infectedindividuals. AIDS. 2010; 24:123-37.FI: 4,909. 1r quartil.135